What Eli Lilly Is Getting With The Acquisition Of Morphic Holding


  • Eli Lilly will acquire Morphic Holding for $3.2 billion, and the deal brings a phase 2b asset MORF-057 for the treatment of inflammatory bowel disease, and a preclinical pipeline.
  • Eli Lilly to acquire Morphic Holding for $3.2 billion, bringing lead asset MORF-057 for IBD treatment.
  • The acquisition provides Eli Lilly a shot on goal in the IBD market, despite potential risks associated with MORF-057 and pipeline.
Documents about mergers and acquisitions m&a with a pen.


Eli Lilly (NYSE:LLY) announced that it will acquire Morphic Holding (NASDAQ:MORF) for $57 per share, or $3.2 billion. The deal brings a lead asset MORF-057, an oral candidate targeting the α4β7 receptor, for the treatment of inflammatory bowel diseases (‘IBD’) such as

Analyst’s Disclosure: I/we have a beneficial long position in the shares of LLY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article reflects the author's opinion and should not be regarded as a buy or sell recommendation or investment advice in any way.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

I publish my best ideas and top coverage on the Growth Stock Forum. If you’re interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button. And to go deeper, sign up for a free trial to Growth Stock Forum.

Leave a Reply

Your email address will not be published. Required fields are marked *